Related Experiment Video
Updated: May 23, 2025

Continuous Video Electroencephalogram during Hypoxia-Ischemia in Neonatal Mice
Published on: June 11, 2020
Neonatal Onset Seizures and Hypotonia Due to D-Bifunctional Protein Deficiency
Sohier Yahia1, Dina Ghozzy1, Yahya Wahba1
1Department of Pediatrics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Insights
Medium-chain triglyceride (MCT) formula shows promise for treating D-bifunctional protein deficiency, a rare inherited peroxisomal disorder. This intervention helped manage seizures and improve symptoms in an infant case.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Peroxisomal disorders (PDs) are inherited conditions affecting peroxisomal function.
- D-bifunctional protein (DBP) deficiency, a type of PD, is linked to HSD17B4 gene mutations and presents as Zellweger-like syndrome.
- Confirmed cases of DBP deficiency are rare.
Purpose of the Study:
- To report a case of D-bifunctional protein deficiency in an infant.
- To investigate the therapeutic potential of medium-chain triglyceride (MCT) formula in managing DBP deficiency symptoms.
Main Methods:
- Clinical presentation analysis of a 6-month-old female infant with neonatal-onset symptoms.
- Biochemical analysis including acylcarnitine profile to detect elevated very long-chain fatty acids.
- Genetic analysis using whole exome sequencing to identify mutations in the HSD17B4 gene.
- Therapeutic intervention with MCT formula and assessment of its effects.
Main Results:
- The infant presented with intractable seizures, hypotonia, facial dysmorphia, and hepatomegaly.
- Acylcarnitine profile indicated elevated very long-chain fatty acids.
- Whole exome sequencing revealed a homozygous missense mutation (c.1444A>T) in the HSD17B4 gene.
- MCT formula administration resulted in seizure control, improved muscle tone, and reduced liver size.
Conclusions:
- This case highlights a potential therapeutic role for MCT-containing formulas in managing D-bifunctional protein deficiency.
- Early diagnosis and intervention with specialized formulas may improve clinical outcomes in patients with DBP deficiency.
Abstract:
Peroxisomal disorders (PDs) are a diverse group of inherited conditions arising from impaired function of a specific peroxisomal enzyme, metabolite transporter, or defect in the peroxisome biogenesis system. Peroxisomal D-bifunctional protein (DBP) deficiency is generally classified as a Zellweger-like syndrome. This disorder is caused by mutations in the HSD17B4 gene, and only a limited number of confirmed cases have been reported to date.The authors report case of a 6-mo-old female infant presenting with neonatal-onset intractable seizures, characteristic facial features, hypotonia, and progressive hepatomegaly. An acylcarnitine profile revealed elevated very long-chain fatty acids, prompting the initiation of a medium-chain triglyceride (MCT) formula. Remarkably, this treatment led to seizure control, improved muscle tone, and a reduction in liver size. Whole exome sequencing identified a homozygous missense mutation in the HSD17B4 gene (c.1444A>T).This case suggests that MCT-containing formulas may offer therapeutic potential in the treatment of D-bifunctional protein deficiency.
Related Concept Videos
Inborn Errors of Metabolism
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Teratogenicity
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Lysosomal Hydrolases

